Tags

Type your tag names separated by a space and hit enter

The efficacy of probiotics in IBS.
J Clin Gastroenterol. 2008 Jul; 42 Suppl 2:S85-90.JC

Abstract

The clear delineation of a postinfective variety of irritable bowel syndrome (IBS), and the description, in a number of studies, of evidence of low-grade inflammation and immune activation in IBS, suggest a role for a dysfunctional relationship between the indigenous flora and the host in IBS and, accordingly, provide a clear rationale for the use of probiotics in this disorder. Other modes of action, including bacterial displacement and alterations in luminal contents, are also plausible. Although clinical evidence of efficacy is now beginning to emerge, a review of available trials emphasizes the importance of clear definition of strain selection, dose, and viability. The possible roles of cotherapy or sequential therapy with antibiotics, probiotics, prokinetics, or other agents, also deserve further study. The role of the enteric flora is evidently an area of great potential in IBS; we are on the threshold of a new era of research and therapy for this common disorder.

Authors+Show Affiliations

Alimentary Pharmabiotic Centre, National University of Ireland, Cork, Ireland. e.quigley@ucc.ie

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18542036

Citation

Quigley, Eamonn M M.. "The Efficacy of Probiotics in IBS." Journal of Clinical Gastroenterology, vol. 42 Suppl 2, 2008, pp. S85-90.
Quigley EM. The efficacy of probiotics in IBS. J Clin Gastroenterol. 2008;42 Suppl 2:S85-90.
Quigley, E. M. (2008). The efficacy of probiotics in IBS. Journal of Clinical Gastroenterology, 42 Suppl 2, S85-90. https://doi.org/10.1097/MCG.0b013e31816244ca
Quigley EM. The Efficacy of Probiotics in IBS. J Clin Gastroenterol. 2008;42 Suppl 2:S85-90. PubMed PMID: 18542036.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of probiotics in IBS. A1 - Quigley,Eamonn M M, PY - 2008/6/11/pubmed PY - 2008/10/7/medline PY - 2008/6/11/entrez SP - S85 EP - 90 JF - Journal of clinical gastroenterology JO - J Clin Gastroenterol VL - 42 Suppl 2 N2 - The clear delineation of a postinfective variety of irritable bowel syndrome (IBS), and the description, in a number of studies, of evidence of low-grade inflammation and immune activation in IBS, suggest a role for a dysfunctional relationship between the indigenous flora and the host in IBS and, accordingly, provide a clear rationale for the use of probiotics in this disorder. Other modes of action, including bacterial displacement and alterations in luminal contents, are also plausible. Although clinical evidence of efficacy is now beginning to emerge, a review of available trials emphasizes the importance of clear definition of strain selection, dose, and viability. The possible roles of cotherapy or sequential therapy with antibiotics, probiotics, prokinetics, or other agents, also deserve further study. The role of the enteric flora is evidently an area of great potential in IBS; we are on the threshold of a new era of research and therapy for this common disorder. SN - 1539-2031 UR - https://www.unboundmedicine.com/medline/citation/18542036/The_efficacy_of_probiotics_in_IBS_ L2 - https://doi.org/10.1097/MCG.0b013e31816244ca DB - PRIME DP - Unbound Medicine ER -